{"nctId":"NCT00444600","briefTitle":"Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema","startDateStruct":{"date":"2007-03"},"conditions":["Diabetic Retinopathy","Diabetic Macular Edema"],"count":691,"armGroups":[{"label":"0.5mg Ranibizumab plus laser","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab + laser"]},{"label":"0.5 mg Ranibizumab plus deferred laser","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab + deferred laser"]},{"label":"4 mg Triamcinolone plus laser","type":"EXPERIMENTAL","interventionNames":["Drug: Triamcinolone Acetonide + laser"]},{"label":"Sham plus laser","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sham injection + laser"]}],"interventions":[{"name":"Triamcinolone Acetonide + laser","otherNames":["corticosteroid"]},{"name":"Ranibizumab + laser","otherNames":["Lucentis, anti-VEGF drug"]},{"name":"Sham injection + laser","otherNames":["placebo"]},{"name":"Ranibizumab + deferred laser","otherNames":["Lucentis, anti-VEGF drug"]}],"eligibilityModule":{"eligibilityCriteria":"General Inclusion Criteria\n\nTo be eligible, the following inclusion criteria (1-5) must be met:\n\n* Age \\>= 18 years\n* Diagnosis of diabetes mellitus (type 1 or type 2)\n* At least one eye meets the study eye criteria\n* Fellow eye (if not a study eye) meets criteria\n* Able and willing to provide informed consent\n\nGeneral Exclusion Criteria\n\nA subject is not eligible if any of the following exclusion criteria are present:\n\n* Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.\n* A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).\n* Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval at the time of study entry.\n* Known allergy to any component of the study drug.\n* Blood pressure \\> 180/110 (systolic above 180 OR diastolic above 110).\n* Major surgery within 28 days prior to randomization or major surgery planned during the next 6 months.\n* Myocardial infarction, other cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization.\n* Systemic anti-vascular growth factor (anti-VEGF) or pro-VEGF treatment within 4 months prior to randomization.\n* For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months.\n* Subject is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the first 12 months of the study.\n\nStudy Eye Inclusion Criteria\n\nThe subject must have one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below. A subject may have two study eyes only if both are eligible at the time of randomization.\n\n* Best corrected electronic Early Treatment Diabetic Retinopathy (E-ETDRS) visual acuity letter score \\<= 78 (i.e., 20/32 or worse) and \\>= 24 (i.e., 20/320 or better) within 8 days of randomization.\n* On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula.\n* Ocular coherence tomography (OCT) central subfield \\>=250 microns within 8 days of randomization.\n* Media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs.\n* If prior macular photocoagulation has been performed, the investigator believes that the study eye may possibly benefit from additional photocoagulation.\n\nStudy Eye Exclusion Criteria\n\nThe following exclusions apply to the study eye only (i.e., they may be present for the nonstudy eye):\n\n* Macular edema is considered to be due to a cause other than diabetic macular edema.\n* An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).\n* An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.)\n* Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).\n* History of treatment for diabetic macular edema at any time in the past 4 months (such as focal/grid macular photocoagulation, intravitreal or peribulbar corticosteroids, anti-VEGF drugs, or any other treatment).\n* History of panretinal (scatter) photocoagulation (PRP) within 4 months prior to randomization.\n* Anticipated need for PRP in the 6 months following randomization.\n* History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization.\n* History of yttrium aluminum garnet (YAG) capsulotomy performed within 2 months prior to randomization.\n* Aphakia.\n* Intraocular pressure \\>= 25 mmHg.\n* History of open-angle glaucoma (either primary open-angle glaucoma or other cause of open-angle glaucoma; note: history of angle-closure glaucoma is not an exclusion criterion).\n* History of steroid-induced intraocular pressure (IOP) elevation that required IOP-lowering treatment.\n* History of prior herpetic ocular infection.\n* Exam evidence of ocular toxoplasmosis.\n* Exam evidence of pseudoexfoliation.\n* Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change in Retinal Thickening of Central Subfield on Optical Coherence Tomography From Baseline to 1 Year","description":"Negative change denotes an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-102","spread":"151"},{"groupId":"OG001","value":"-131","spread":"129"},{"groupId":"OG002","value":"-137","spread":"136"},{"groupId":"OG003","value":"-127","spread":"140"}]}]}]},{"type":"SECONDARY","title":"Number of Injections in First Year","description":"Maximum possible number of injections for each of the following groups: sham+prompt laser=13 sham injections;ranibizumab+prompt laser=13 ranibizumab injections; ranibizumab+deferred laser=13 ranibizumab injections; triamcinolone+prompt laser=4 triamcinolone injections and 9 sham injections.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity","description":"Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"13"},{"groupId":"OG001","value":"9","spread":"11"},{"groupId":"OG002","value":"9","spread":"12"},{"groupId":"OG003","value":"4","spread":"13"}]}]}]},{"type":"PRIMARY","title":"Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year","description":"Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Central Subfield Thickness < 250 With at Least a 25 Micron Decrease From Baseline to 1 Year","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"74","spread":null},{"groupId":"OG003","value":"82","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Distribution of Logarithmic Transformation of Optical Coherence Tomography (LogOCT) Improvement and Worsening","description":"Logarithmic transformation of optical coherence tomography central subfield thickness is calculated by taking the log base 10 of the ratio of the central subfield thickness divided by 200 and rounding to the nearest hundredth. The change is the change in the log values.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"71","spread":null},{"groupId":"OG003","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"13"},{"groupId":"OG001","value":"9","spread":"10"},{"groupId":"OG002","value":"10","spread":"14"},{"groupId":"OG003","value":"2","spread":"14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":"14"},{"groupId":"OG001","value":"8","spread":"12"},{"groupId":"OG002","value":"7","spread":"9"},{"groupId":"OG003","value":"8","spread":"9"}]}]}]},{"type":"PRIMARY","title":"Change in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"14"},{"groupId":"OG001","value":"9","spread":"12"},{"groupId":"OG002","value":"11","spread":"13"},{"groupId":"OG003","value":"3","spread":"13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"13"},{"groupId":"OG001","value":"9","spread":"10"},{"groupId":"OG002","value":"8","spread":"12"},{"groupId":"OG003","value":"5","spread":"13"}]}]}]},{"type":"PRIMARY","title":"Change in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score","description":"Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"12"},{"groupId":"OG001","value":"6","spread":"10"},{"groupId":"OG002","value":"5","spread":"13"},{"groupId":"OG003","value":"1","spread":"11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"14"},{"groupId":"OG001","value":"12","spread":"11"},{"groupId":"OG002","value":"13","spread":"10"},{"groupId":"OG003","value":"7","spread":"14"}]}]}]},{"type":"PRIMARY","title":"Change in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness","description":"Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"11"},{"groupId":"OG001","value":"7","spread":"11"},{"groupId":"OG002","value":"7","spread":"12"},{"groupId":"OG003","value":"3","spread":"12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"15"},{"groupId":"OG001","value":"11","spread":"10"},{"groupId":"OG002","value":"11","spread":"13"},{"groupId":"OG003","value":"6","spread":"14"}]}]}]},{"type":"PRIMARY","title":"Change in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity","description":"Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"13"},{"groupId":"OG001","value":"10","spread":"11"},{"groupId":"OG002","value":"9","spread":"12"},{"groupId":"OG003","value":"3","spread":"14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"15"},{"groupId":"OG001","value":"8","spread":"10"},{"groupId":"OG002","value":"9","spread":"13"},{"groupId":"OG003","value":"5","spread":"12"}]}]}]},{"type":"PRIMARY","title":"Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator","description":"Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"13"},{"groupId":"OG001","value":"8","spread":"11"},{"groupId":"OG002","value":"8","spread":"13"},{"groupId":"OG003","value":"3","spread":"11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"14"},{"groupId":"OG001","value":"10","spread":"9"},{"groupId":"OG002","value":"8","spread":"15"},{"groupId":"OG003","value":"3","spread":"13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"13"},{"groupId":"OG001","value":"9","spread":"12"},{"groupId":"OG002","value":"10","spread":"10"},{"groupId":"OG003","value":"5","spread":"14"}]}]}]},{"type":"SECONDARY","title":"Number of Laser Treatments Received Prior to the 1 Year Visit","description":"One eye in the sham+prompt laser group did not receive laser until post 1-year due to an adverse event unrelated to study treatment. One eye in the triamcinolone+prompt laser did not receive laser until after 1-year due to missing 2 consecutive visits at the time of required laser treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"124","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Eyes With Alternative Treatments Prior to the 1-year Visit","description":"Each combination of treatment only counted once.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Moderately Severe Non-proliferative Diabetic Retinopathy or Better From Baseline to 1-year","description":"113 eyes had missing or ungradable photos at 1 year. Criteria are based on the ETDRS fundus photographic risk factors for the progression of diabetic retinopathy. ETDRS report no. 12. Ophthalmology 1991; 98:823-833","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Severe Non-proliferative Diabetic Retinopathy or Worse From Baseline to 1-year","description":"Criteria are based on the ETDRS fundus photographic risk factors for the progression of diabetic retinopathy. ETDRS report no. 12. Ophthalmology 1991; 98:823-833, ETDRS Severity Scale = Diabetic retinopathy absent, minimal non-proliferative diabetic retinopathy (PDR), mild to moderately severe non-PDR, severe non-PDR, scars of full pr partial panretinal photocoagulation present PDR absent, mild to moderate PDR, high risk PDR, cannot grade, missing.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Eyes Receiving Laser at the 48 Week Visit (%)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cardiovascular Events According to Antiplatelet Trialists' Collaboration Through 1 Year","description":"Antiplatelet Trialists' Collaboration is a collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. MBJ 1994; 308:81-106. Nonfatal cerebrovascular accident includes ischemic or hemorrhagic or unknown events. Vascular death includes death from any potential vascular or unknown cause.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Optical Coherence Tomography Retinal Volume at 1 Year","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"1.4"},{"groupId":"OG001","value":"7.3","spread":"1.0"},{"groupId":"OG002","value":"7.4","spread":"1.2"},{"groupId":"OG003","value":"7.5","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.4"},{"groupId":"OG001","value":"-1.4","spread":"1.4"},{"groupId":"OG002","value":"-1.5","spread":"1.5"},{"groupId":"OG003","value":"-1.4","spread":"1.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Major Ocular Adverse Events During First Year of Follow-Up","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":53,"n":130},"commonTop":["Vision Blurred","Eye pain","Intraocular pressure increased","Conjunctival haemorrhage","Cataract"]}}}